Tech Company Financing Transactions
Lycera Funding Round
Private investors invested in a $29.9 million Series B funding round for Lycera. The round was announced on 6/22/2015.
Transaction Overview
Company Name
Announced On
6/22/2015
Transaction Type
Venture Equity
Amount
$29,892,748
Round
Series B
Investors
Proceeds Purpose
Amount includes Conversion of Convertible Promissory Notes for Series B Preferred Stock and the purchase of Series B-1 Preferred Stock for cash. Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1350 Highland Dr. A
Ann Arbor, MI 48108
USA
Ann Arbor, MI 48108
USA
Phone
Website
Email Address
Overview
Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera's technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Jeffrey Wilkins
President
Alex Howarth
Vice President
Laura Carter
Vice President
JoAnn Scatina
Vice President
Peter Toogood
Browse more venture capital transactions:
Prev: 6/22/2015: Loopd venture capital transaction
Next: 6/22/2015: gatheredtable venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs